SCHEDULE 13G/A: Insider Allen Baharaff Discloses 2.6% Stake in Galmed Pharmaceuticals Following Share Split and Corporate Dissolution

Allen Baharaff, a former controlling shareholder of G. Yarom Medical Research Ltd., reported a 2.6% beneficial ownership in Galmed Pharmaceuticals Ltd. as of December 31, 2024, following a reverse share split and the dissolution of G. Yarom Medical Research Ltd.

Summary

• Allen Baharaff reported beneficial ownership of 44,128 ordinary shares of Galmed Pharmaceuticals Ltd. as of December 31, 2024.
• This ownership represents 2.6% of the Issuer's ordinary shares outstanding.
• The reported shares include 17,778 directly owned ordinary shares, 16,081 ordinary shares issuable upon the exercise of options and RSUs within 60 days after December 31, 2024, and 10,269 ordinary shares distributed from G. Yarom Medical Research Ltd.
• G. Yarom Medical Research Ltd., where Mr. Baharaff served as controlling shareholder and chairman, voluntarily dissolved and wound up its operations on September 30, 2024, distributing its assets pro rata to its members.
• The reported share count reflects a one-for-twelve reverse share split of Galmed Pharmaceuticals Ltd.'s Ordinary Shares, which became effective on August 29, 2024.
• The percentage of ownership is calculated based on 1,664,883 ordinary shares issued and outstanding as of December 31, 2024, plus the 16,081 ordinary shares issuable from options and RSUs.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership, with no inherent positive or negative sentiment regarding company performance or outlook. It simply updates a shareholder's stake.

Future Outlook

NA

Industry Context

This document is a routine regulatory disclosure of beneficial ownership by an individual, providing transparency on significant holdings. It does not offer insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual's ownership stake in the company, including the source of some shares from a dissolved entity and the impact of a reverse share split.

Key Dates

Keywords

Galmed Pharmaceuticals, Allen Baharaff, Schedule 13G, beneficial ownership, ordinary shares, reverse share split, G. Yarom Medical Research Ltd., SEC filing